- Home
- CRGX vs OLP Comparison
CRGX vs OLP Comparison
Compare CRGX & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- OLP
- Stock Information
- Founded
- CRGX 2021
- OLP 1982
- Country
- CRGX United States
- OLP United States
- Employees
- CRGX N/A
- OLP N/A
- Industry
- CRGX
- OLP Real Estate Investment Trusts
- Sector
- CRGX
- OLP Real Estate
- Exchange
- CRGX Nasdaq
- OLP Nasdaq
- Market Cap
- CRGX 628.6M
- OLP N/A
- IPO Year
- CRGX 2023
- OLP N/A
- Fundamental
- Price
- CRGX $3.86
- OLP $25.92
- Analyst Decision
- CRGX Hold
- OLP Strong Buy
- Analyst Count
- CRGX 7
- OLP 1
- Target Price
- CRGX $4.67
- OLP $28.00
- AVG Volume (30 Days)
- CRGX 1.9M
- OLP 46.6K
- Earning Date
- CRGX 03-20-2025
- OLP 03-04-2025
- Dividend Yield
- CRGX N/A
- OLP 7.06%
- EPS Growth
- CRGX N/A
- OLP 51.11
- EPS
- CRGX N/A
- OLP 1.63
- Revenue
- CRGX N/A
- OLP $89,142,000.00
- Revenue This Year
- CRGX N/A
- OLP N/A
- Revenue Next Year
- CRGX N/A
- OLP $4.71
- P/E Ratio
- CRGX N/A
- OLP $15.65
- Revenue Growth
- CRGX N/A
- OLP N/A
- 52 Week Low
- CRGX $3.00
- OLP $19.75
- 52 Week High
- CRGX $33.92
- OLP $30.45
- Technical
- Relative Strength Index (RSI)
- CRGX 20.88
- OLP 45.92
- Support Level
- CRGX $3.00
- OLP $25.27
- Resistance Level
- CRGX $3.88
- OLP $25.93
- Average True Range (ATR)
- CRGX 0.92
- OLP 0.50
- MACD
- CRGX -1.00
- OLP 0.12
- Stochastic Oscillator
- CRGX 5.99
- OLP 71.79
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.